Squamous cell lung cancer: from tumor genomics to cancer therapeutics.
Squamous cell lung cancer: from tumor genomics to cancer therapeutics.
复制标题
DOI：
10.1158/1078-0432.ccr-14-3039
复制
发表时间：
2015-05-15
期刊：
影响因子：
--
通讯作者：
Hirsch FR
中科院分区：
文献类型：
--
作者：
Gandara DR;Hammerman PS;Sos ML;Lara PN Jr;Hirsch FR
鳞状细胞肺癌(SCC)是肺癌研究中一个尚未得到满足的领域。在过去的几年里，鳞癌的治疗进展落后于现在更常见的非小细胞肺癌组织学亚型腺癌。然而，最近关于确定鳞状细胞癌潜在的复杂生物学的努力已经开始在多种方面取得成果，包括表征以前未知的基因组和信号通路，描绘新的潜在的可操作的分子靶点，以及随后针对独特的鳞状细胞癌相关分子异常的大量药物的开发。新治疗药物的SCC特异性预后基因标记和预测生物标记物首次出现。此外，最近和正在进行的临床试验，包括肺MAP主方案，旨在促进靶向治疗-生物标记物组合的批准。在这篇综合综述中，我们描述了鳞癌治疗的现状，对鳞癌生物学和预后基因信号的理解的最新进展，以及创新的新的临床试验的发展，所有这些都为晚期鳞癌患者提供了新的希望。
Squamous cell lung cancer (SCC) represents an area of unmet need in lung cancer research. For the last several years, therapeutic progress in SCC has lagged behind the now more common NSCLC histologic subtype of adenocarcinoma. However, recent efforts to define the complex biology underlying SCC have begun to bear fruit in a multitude of ways, including characterization of previously unknown genomic and signaling pathways, delineation of new potentially actionable molecular targets, and subsequent development of a large number of agents directed against unique SCC-associated molecular abnormalities. For the first time, SCC-specific prognostic gene signatures and predictive biomarkers of new therapeutic agents are emerging. In addition, recent and ongoing clinical trials, including the Lung-MAP master protocol, have been designed to facilitate approval of targeted therapy-biomarker combinations. In this comprehensive review we describe the current status of SCC therapeutics, recent advances in the understanding of SCC biology and prognostic gene signatures, and the development of innovative new clinical trials, all of which offer new hope for patients with advanced SCC.